At ELECTRONICA, ITEN Present an Autonomous Asset Monitoring Solution Based on a 100µA.h Micro-Battery!
10.11.2022 18:55:00 EET | Business Wire | Press release
ITEN, the deep tech company, which just closed a financing round of 80M€ to become a key player in the manufacture of solid-state lithium-ion micro-batteries, shall take the opportunity of next ELECTRONICA exhibition to present a breakthrough in the way of powering autonomous embedded systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005719/en/
Ecofriendly and powerful soli-state micro-battery able to recharge in a few minutes. (Photo: ITEN)
When observing the battery-powered electronic solutions, ITEN came indeed to the following conclusions:
- A lot of electronic designs relies on very polluting coin cells, difficult to assemble on Printed Circuit Boards, costly to recycle and requiring periodic maintenance to replace the battery once empty.
- Depending on the countries, only 30 to 50% of such coin cells are effectively recycled.
- Autonomous embedded systems require less and less energy to operate; however, from time to time, the power supply must deliver high current pulses for instance to drive RF transceivers or actuators; therefore, most electronic designers must use oversized coin cells because such batteries are known to deliver only small currents.
From a battery standpoint, this means that a lower battery capacity could be used if the battery would be able to deliver the required power and could be recharged regularly.
This is precisely what ITEN shall demonstrate during ELECTRONICA: ITEN shall indeed present an autonomous asset monitoring solution, including sensors and a Bluetooth Low Energy (BLE) System-on-a-chip, and powered by the combination of an indoor photovoltaic cell from DRACULA Technologies (LAYERR Technology) and ITEN’s powerful rechargeable SMD micro-battery of only 100µA.h. The solution operating 24/7 can send data every 10 seconds during the day and every 4 to 5 minutes during the night (this frequency could be increased if using a 250µA.h micro-battery instead). By comparison, a coin cell of at least 100mA.h would be required to get the same operating conditions but with a limited lifetime.
By extension, similar designs could be used in applications like BLE asset tracking, BLE tags, beacons, and sensor data loggers.
On stand B4-120, ITEN shall also demo micro-batteries used as a back-up power supply to keep some clocks or microcontrollers active or to send maintenance alerts in case of failure of the main power source.
By doing so, ITEN clearly reassert their strategy to progressively replace most of the coin cells used worldwide by ecofriendly rechargeable SMD micro-batteries containing neither heavy metals, nor toxic materials, nor organic solvents and showing a carbon footprint 200 to 1000 times less compared to coin cells.
After 8 years of R&D, ITEN have been granted more than 200 patents worldwide. ITEN are an integrated device manufacturer, controlling the complete production chain from nanomaterial synthesis up to the battery packaging and test. Even with low capacities, ITEN micro-batteries can deliver power and high current pulses. They are a concrete response to electronics designers looking for ecofriendly alternatives to coin cells. In this respect, ITEN solutions fit in with the European Directive recommending getting rid of non-rechargeable batteries in all electronic system designs from year 2030.
About ITEN:
ITEN is the leading company developing and manufacturing ecofriendly solid-state lithium-ion SMD micro batteries. Such micro batteries are rechargeable In a few minutes and can deliver power over a wide operating temperature range. They are used in many applications as back-up power supply, or to power autonomous sensor nodes or in applications like tracking and monitoring, smartphone peripherals, smart cards, medical devices, home and building automation, smart cities, wearables, and e-textiles.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005719/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
